DCF NewsLETTERVol. 15 No. 159 • JANUARY 2012 • PRICE `1.50 PER COPY

Dear Friends,

We have taken another pioneering step by introducing another World Class Imaging Technology.

We introduce 1ST TIME IN DELHI – High Defi nition (HD) PET. CT with ultrafast LSO Crystal Technology. Highlights of PET. CT are in the facing column.

Dr. Prof. Sharan Choudhri has joined us as Senior Consultant and HOD in the Department of Surgical Oncology. He has brought with him wealth of knowledge and clinical experience accumulated in a career spanning over three decades in the Army Medical Corps. He established the fi rst Malignant Diseases Treatment Centre for the Indian Air Force at Command Hospital Air Force, Bangalore, and the Oncology Centre at Base Hospital, Delhi Cantt. He honed his operative skills and clinical acumen in the Services, and he was appointed as Senior Advisor in Surgical Oncology to the entire Indian Armed Forces. He is a recognized guide for DNB students (Surgical Oncology) He is a recipient of the following medals / awards:

• Air Vice Marshal MM Shrinagesh Memorial Medal for standing First in Surgery at AFMC, Pune – 1986.

• UICC-ICRETT Fellowship Award at Kurume Medical University, Kurume, Japan as Visiting Fellow for “Three-Field Lymphadenectomy for Esophageal Malignancies”.

• UICC-ICRETT Fellowship Award to carry out Research Project on “Sentinel Lymph Node Mapping and Biopsy in Surgical Oncology – Its Technique, Pitfalls and Outcome” at Michigan State University, Flint, Michigan, USA.

• “Young Investigators Award” at the 3rd International Sentinel Node Congress at Yokohama, Japan 16 – 18 Nov. 2002, where his presentation on “Promise and Pitfalls of Sentinel Lymph Node Biopsy in Oral Malignancies” was selected for Outstanding Scientifi c Merit, Innovation and Educational Value and Promotion of Sentinel Node Navigation Surgery.

Our National Oncology Conference on “Lung Cancer – Old Problems, New Solutions” is being organized on 29th January 2012 at Hotel Hilton, Double Tree, 13 Mayur Vihar, Phase – I, Delhi – 110 091.Kindly see the scientifi c programme on page 3 and get yourself registered as an early bird on discounted rates.

Looking forward to seeing you on 29th January 2012.

Dr. S. KhannaExecutive Director

HIGHLIGHTS OF OUR PET. CT

Unique Technical Features• Latest Generation PET. CT with ultrafast LSO Crystal Technology. • Scans entire body and provides fused images of the PET and CT (Anatometabolic Imaging).• World’s best PET resolution (2mm) for detection of smallest tumors.• Accurate SUV (System Uptake Value) quantifi cation and full HD lesion detection with motion-frozen images.• High performance Spiral CT scanner with HRCT, 3D CT, CT Angiography, Dental CT and CT Endoscopy.

Clinical Benefi ts• Helps in early detection and accurate staging of cancer.• Helps to take accurate guided biopsy samples from the suspected cancer lesions and relapsed lesions.• Helps in early evaluation of response to therapy.• Helps in accurate analysis of cancer treatment and follow up.• Helps in early diagnosis of Dementias and Epilepsies.

High Defi nition (HD) PET. CT with LSO Crystal Technology

Prof. (Dr.) Sharan ChoudhriMS (General Surgery), DNB (Surgery)Senior Consultant and HOD - Surgical Oncology

Patient’s Comfort and Safety• Provides enhanced patient comfort with high speed acquisition and lower retake exams due to improved image quality. • No claustrophobia because of wide gantry aperture and slim table.• Provides enhanced patient safety with fully automated real-time dose modulation. Upto 65% dose reduction with full diagnostic image quality.PET. CT Indications • Staging of cancer which potentially can be treated radically e.g. small cell lung cancer.• Establish baseline staging before commencing treatment e.g. GIST. • Evaluation of an indeterminate lesion e.g. solitary lung nodule. • Assessment of response to therapy.• Evaluation of suspected disease recurrence / relapse / residual disease e.g. lymphoma, testicular seminoma.• To guide biopsy e.g. pleural biopsy for mesothelioma.PET. CT as an Aid• Occult primary lesion e.g. non-metastatic manifestation of neoplastic disease. • Evaluation of suspected recurrence in patients with equivocal conventional imaging.• Evaluation of residual disease with negative/ equivocal conventional imaging - in patients with treated differentiated thyroid carcinoma and treated medullary thyroid carcinoma.• Prior knowledge to radical nodal resection - in patients with metastatic melanoma.• Suspected malignant transformation - in plexiform neurofi bromata (type 1 neurofi bromatosis).• Differentiate between radiation-induced necrosis and tumor recurrence e.g. brain tumors.• PUO (Pyrexia of unknown origin) for more than three weeks to aid in identifi cation on disease origin.

Specifi c Clinical Conditions requiring PET. CTHead/Neck Cancer1. Detection of occult primary tumors in patients presenting with metastatic disease.2. Initial staging – including detection of cervical lymph node metastases in the clinically node negative neck, and detection of distant metastases in patients with locally advanced disease.3. Detection of residual or recurrent disease.Thyroid Cancer1. Detection of residual or recurrent thyroid cancer when serum thyroglobulin is elevated and radioiodine scan is negative.2. Staging of patients with poorly differentiated thyroid cancers. 3. Evaluation of treatment response following systemic or local therapy of metastatic or locally invasive disease.

NATIONAL ONCOLOGY CONGRESS – 2012 Sunday, 29th of January 2012Dear Colleagues and Friends,

We are pleased and honoured to invite you to the “National Oncology Congress 2012” being organized by Dharamshila Hospital and Research Centre on Sunday, 29th of January 2012, under the aegis of Dharamshila Cancer Foundation And Research Centre. The Congress is being organized to highlight the Current scenario in Management of Lung Cancer including recent trends in the diagnosis and the role of surgery, chemotherapy and radiotherapy, in the management of this common tumor. Considering the rising incidence of Lung Cancer, we felt the need to raise this topic as part of a full day conference which will address recent advances in its management. Eminent speakers and specialists from all over the country will share with us their expertise and experiences in delivering optimal care to patients with Lung Cancer, using newer modalities and protocols. Diagnosis and management of these tumors is well recognized and we will enlighten the delegates about the newer techniques in this area. The scientifi c sessions will cover all these and more. This will be a platform for all doctors involved in the care of patients with Lung Cancer and for students to interact with our esteemed faculty, who are established leaders in their respective areas of Lung Cancer Management. Members of the Organizing Committee extend you a warm welcome and invite you and your friends to join us for this event. You will not only enjoy the scientifi c deliberation but also get a chance to enjoy Delhi hospitality at its best, and see a changed and modern Delhi, during one of the best months of the year.

Looking forward to your active participation and wishing you all a Very Happy and Prosperous New Year 2012

Dr. Meenu Walia Prof. (Dr.) R. DawarOrganizing Secretary Chairperson

Vol. 15 No. 159 • JANUARY 2012

Breast Cancer1. Initial staging of patients with locally advanced or metastatic breast cancer when conventional staging studies e.g. CT or bone scan are equivocal or suspicious.2. Follow-up or surveillance patients with breast cancer when conventional studies e.g. CT or bone scan are equivocal or suspicious.Esophageal Cancer• Initial staging.• Restaging after neoadjuvant chemoradiation therapy.• Delineation of gross tumor volume in patients receiving radiation therapy.Colorecal Cancer• Preoperative evaluation of patients with potentially resectable hepatic or other metastases.• Determining location of tumors when rising CEA level suggests recurrence. Cervical Cancer• Initial treatment planning assistance, including determination of nodal status and systemic spread.• Detection of residual or recurrent disease following initial treatment.Melanoma• Detection and localization of potential extranodal metastatic lesions in initial evaluation of patients with advanced stage disease.• Evaluate the extent of metastatic disease burden in patients with recurrent disease following treatment.NeurologyRefractory Epilepsy: Interictal FDG-PET is recommended for lateralization of epileptogenic foci prior to surgical intervention in patients with medically refractory epilepsy and where inconclusive localising information is provided by a standard assessment, including seizure pattern, electroencephalography and MRI.Dementia: In the work-up of patients with dementia, FDG-PET is helpful in identifi cation of early Alzheimer’s disease before the onset of cerebral atrophy, especially in younger patients with dementia and normal MRI or CT.Unknown Primary with Lymph Nodes Secondaries: (e.g. cervical lymphadenopathy)• To identify primary tumor.• Suspected recurrence with rising tumor markers.

Inspite of extremely expensive high-end technology, our rates are same as the institutions having basic PET technology. For any clarifi cation/appointment contact us at 011 43066576, 8130000120 or mail us at radiology@dhrc.net.in contact@dhrc.inDr. Arun GeraConsultant Nuclear Medicine

Vol. 15 No. 159 • JANUARY 2012

National Oncology Congress 2012Lung Cancer – Old Problems, New Solutions

Sunday, 29th January 2012 at Double Tree by Hilton13 Mayur Vihar District Centre, Delhi- 110096

SESSION I – DIAGNOSIS OF LUNG CANCER• Role of PET CT in Staging and Follow-up of Lung Cancer.• Recent advances in Morphological and Molecular Approach to Lung Cancer• Discussion and Questions

SESSION II – NON SMALL CELL LUNG CANCER (NSCLC)• Management of Early NSCLC• Surgical Approach to Locally Advanced NSCLC • Chemotherapy in Advanced NSCLC • Targeted Therapy in Advanced NSCLC• Recent Advances in Radiotherapy in Locally Advanced NSCLC• Discussion and Questions

Programme

T E A B R E A K

Registration Form(Kindly fi ll this form in Capital Letters only)

Name ………………………………………………………………Designation………………......………………..…Institution………………..……………Residential Address………………………………………………………………..............................................................................................................City ......………………………State ......……………………… Pin ......……………………… Tel (Off) ......……………………… (Res.) ......…………………Mobile …………………………………………. Email ………………..………………..………….....

Signature of the Sponsoring Authority with Seal (if any)

Payment Details (Only DD will be accepted from Outstation Delegates) Chq. No. / DD No. …………....... Cash………… Amount…………............Amount in Words ………………….…………..……………………………….........……………………The Cheques / DD should be made in favour of “Dharamshila Cancer Foundation And Research Centre” payable at New Delhi.

Signature of the DelegatePlease Post the Registration Form to ‘Conference Secretariat, Dharamshila Hospital And Research Centre’, Vasundhara Enclave, Delhi – 110096Tel: 43066360, 43066356 Email: dhrc_conference@dhrc.in dchrc@hotmail.com

** The delegate kit for spot registration is subject to availability

Registration Details

DHRC ORATION

SESSION V – ONCO QUIZ ON LUNG CANCER• Valedictory Function (Vote of Thanks)

SESSION III – SMALL CELL LUNG CANCER (SCLC)• Spectrum of Neuro-endocrine Lung Tumors• Management of SCLC • Discussion and Questions

SESSION IV – MEET THE EXPERTS• Management of High Risk Patients of Lung Cancer• Maintenance Treatment in Advanced NSCLC• Oligometastatic NSCLC

L U N C H

T E A B R E A K

Vol.

15

No.

159 •

JA

NU

ARY

2012